Skip to content
Who seeks “further clarification” from Bharat Biotech to proceed with the final assessment of Covaxin


The World Health Organization technical advisory group met on Tuesday to review data on Covaxin from Bharat Biotech for the emergency use list (EUL) of the vaccine made in India.

The technical advisory group has requested “further clarification” from Bharat Biotech for its COVID-19 vaccine in order to conduct a final risk-benefit assessment.

The group will now meet on November 3 for a final assessment. Hyderabad-based Bharat Biotech, which developed Covaxin, had submitted an EOI (expression of interest) to the WHO on April 19 for the vaccine’s Emergency Use List (EUL).

WHO told CNBC TV18: “There was a meeting of the Emergency Use List Advisory Group (TAG-EUL), an independent advisory group that provides recommendations to WHO on the issue of find out if a Covid 19 vaccine can be listed for emergency use under the EUL procedure. “

“The TAG met today (October 26, 2021) and decided that further clarification from the manufacturer is needed to conduct a final risk and benefit assessment of EUL for global vaccine use. “

The TAG expects to receive these clarifications from the manufacturer by the end of this week, and aims to meet again for the final risk-benefit assessment on Wednesday, November 3, the WHO said.

The Technical Advisory Group for the Emergency Use List is an independent advisory group that provides recommendations to WHO on whether a Covid 19 vaccine can be listed for emergency use under the EUL procedure.

With contributions from the agency

First publication: STI

.


cnbctv18-forexlive-benzinga

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.